|

GD2-SADA:177Lu-DOTA Complex Clinical Trials

1 actively recruiting trial across 1 location

Also known as: two-step radioimmunotherapy

Pipeline

Phase 1: 1

Top Sponsors

  • Y-mAbs Therapeutics1

Indications

  • SCLC1
  • High-risk Neuroblastoma1
  • Malignant Melanoma1
  • Sarcoma1
  • Lung Cancer1

Scottsdale, Arizona1 trial

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

HonorHealth

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.